Isoray Completes Merger with Viewpoint Molecular Targeting

IBA Acquires ORA Group to Expand Nuclear Medicine Capabilities

December 19, 2025

Medical Devices

Ion Beam Applications S.A. (IBA) has acquired ORA Group (ORA - Optimized Radiochemical Applications SRL and OOC) to strengthen its leadership in nuclear medicine and radiochemistry. The cash-free, debt-free transaction (total consideration €15–20 million) is financed from IBA’s own funds and existing credit facilities and is immediately accretive to IBA Technologies’ revenue and EBITDA; ORA founder Vincent Tadino will continue with the combined business as CTO.

Tenpoint Therapeutics and Visus Therapeutics Complete Merger to Advance Ophthalmic Pipeline

December 12, 2024

Biotechnology

Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. completed a merger to combine their ophthalmic drug development programs, bringing the late-stage presbyopia candidate BRIMOCHOL PF together with Tenpoint’s broader aging-eye pipeline. The combined company is launching a crossover financing round with participation from institutional investors to support an NDA filing and a planned US commercial launch of BRIMOCHOL PF in the 1H of 2026. Henric Bjarke was named CEO of the merged company.

Bristol Myers Squibb Acquires RayzeBio for Approximately $4.1 Billion

December 26, 2023

Biotechnology

Bristol Myers Squibb will acquire radiopharmaceutical developer RayzeBio in an all-cash tender offer of $62.50 per share, valuing RayzeBio at approximately $4.1 billion (about $3.6 billion net of cash). The acquisition brings RayzeBio's actinium-based radiopharmaceutical platform, a Phase 3 lead program (RYZ101) and in-house radiopharmaceutical manufacturing capabilities into Bristol Myers Squibb's oncology franchise to accelerate development and commercialization of targeted radiopharmaceutical therapeutics.

Syros Pharmaceuticals Merges with TYME Technologies

September 16, 2022

Biotechnology

Syros Pharmaceuticals completed a merger with TYME Technologies, acquiring TYME's pipeline assets and approximately $60 million of net cash at closing. The transaction was accompanied by an oversubscribed $130 million PIPE financing to provide capital for Syros' late-stage hematology programs and early commercialization activities.

Novartis Acquires Mariana Oncology

May 2, 2024

Biotechnology

Novartis will acquire Mariana Oncology for $1 billion upfront and up to $750 million in milestone payments, bringing Mariana's peptide-based radiopharmaceutical pipeline and manufacturing capabilities into Novartis. The deal adds radioligand therapeutic discovery, isotope supply chain and manufacturing know-how to Novartis to accelerate development and commercialization of targeted cancer therapies.

Bruker Corporation Acquires Canopy Biosciences, LLC

September 11, 2020

Biotechnology

Bruker Corporation has acquired Canopy Biosciences, LLC to strengthen its targeted multi-omics and high-plex biomarker imaging capabilities, adding Canopy's ChipCytometry platform and multi-omics services. Financial terms were not disclosed; Ampersand Capital Partners was identified as Canopy's lead investor.